MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors

Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Cancer Cell (Impact Factor: 23.89). 01/2005; 6(6):587-96. DOI: 10.1016/j.ccr.2004.10.015
Source: PubMed

ABSTRACT To better understand the origin of leukemic stem cells, we tested the hypothesis that all leukemia oncogenes could transform committed myeloid progenitor cells lacking the capacity for self-renewal, as has recently been reported for MLL-ENL. Flow-sorted populations of common myeloid progenitors and granulocyte-monocyte progenitors were transduced with the oncogenes MOZ-TIF2 and BCR-ABL, respectively. MOZ-TIF2-transduced progenitors could be serially replated in methylcellulose cultures and continuously propagated in liquid culture, and resulted in an acute myeloid leukemia in vivo that could be serially transplanted. In contrast, BCR-ABL transduction conferred none of these properties to hematopoietic progenitors. These data demonstrate that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death.

Download full-text


Available from: Ifor R Williams, Jul 27, 2015
  • Source
    • "These fusion genes produce the same disease pattern with blast cells of a monocytoid phenotype. Previous studies have revealed that KAT6A is essential for the self-renewal of hematopoietic stem cells (Katsumoto et al., 2006; Thomas et al., 2006), and KAT6A fusion proteins enable the transformation of non-self-renewing myeloid progenitors into leukemia stem cells (Huntly et al., 2004). Other data have shown that KAT6A cooperates with MLL to regulate HOX gene expression in human cord blood CD341 cells (Paggetti et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The monocytic leukemia zinc finger protein KAT6A (formerly MOZ) gene is recurrently rearranged by chromosomal translocations in acute myeloid leukemia (AML). KAT6A is known to be fused to several genes, all of which have histone acetyltransferase (HAT) activity and interact with a number of transcription factors as a transcriptional coactivator. The present study shows that the leucine twenty homeobox (LEUTX) gene on 19q13 is fused to the KAT6A gene on 8p11 in a therapy-related AML with t(8;19)(p11;q13) using the cDNA bubble PCR method. The fusion transcripts contained 83 nucleotides upstream of the first ATG of LEUTX and are presumed to create in-frame fusion proteins. LEUTX is known to have a homeobox domain. Expression of the LEUTX gene was only detected in placenta RNA by RT-PCR, but not in any tissues by Northern blot analysis. The putative LEUTX protein does not contain any HAT domain, and this is the first study to report that KAT6A can fuse to the homeobox gene. The current study, with identification of a new partner gene to KAT6A in a therapy-related AML, does not elucidate the mechanisms of leukemogenesis in KAT6A-related AML but describes a new gene with a different putative function. © 2014 Wiley Periodicals, Inc.
    Genes Chromosomes and Cancer 04/2014; 53(4). DOI:10.1002/gcc.22140 · 3.84 Impact Factor
  • Source
    • "; Table S1 available online). We then functionally evaluated the effect of knocking down these genes on Cebpa KO cells (Mx1-Cre + Cebpa loxP/loxP ; from here on referred to as Cebpa KO following Cre-mediated deletion) after serially replating in methylcellulose cultures, a cell culture assay that has been correlated with the ability to induce leukemia in mice (Huntly et al., 2004; Lavau et al., 1997; Moran-Crusio et al., 2011). We transduced Cebpa KO LSK cells with lentiviruses carrying either a mix of scrambled small hairpin RNA (shRNA) (control) or a pool of five shRNAs all targeting one specific candidate and assessed their capability to undergo serial replating (Figure S1A). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutation or epigenetic silencing of the transcription factor C/EBPα is observed in ∼10% of patients with acute myeloid leukemia (AML). In both cases, a common global gene expression profile is observed, but downstream targets relevant for leukemogenesis are not known. Here, we identify Sox4 as a direct target of C/EBPα whereby its expression is inversely correlated with C/EBPα activity. Downregulation of Sox4 abrogated increased self-renewal of leukemic cells and restored their differentiation. Gene expression profiles of leukemia-initiating cells (LICs) from both Sox4 overexpression and murine C/EBPα mutant AML models clustered together but differed from other types of AML. Our data demonstrate that Sox4 overexpression resulting from C/EBPα inactivation contributes to the development of leukemia with a distinct LIC phenotype.
    Cancer cell 10/2013; 25(2). DOI:10.1016/j.ccr.2013.09.018 · 23.89 Impact Factor
  • Source
    • "3. LICs and disease progression: lessons from chronic myelogenous leukemia Chronic myelogenous leukemia (CML) is universally considered a stem cell disorder based on detection of the Ph chromosome , the genetic lesion responsible for generating the oncogenic BCR/ABL protein that causes the disease (Ren, 2005), in multiple hematopoietic cell types (Haferlach et al., 1997) and classical genetic studies demonstrating clonal glucose-6- phosphate dehydrogenase (G6PD) isoenzyme expression in multiple hematopoietic lineages including B-cells (Fialkow et al., 1977; Martin et al., 1980). Additional evidence in support of the notion that the HSC is the cell of origin in CML derives from studies demonstrating that BCR/ABL can transform stem cell-enriched murine Lin-Sca-1+Kit+ cells but not the GMP subset (Huntly et al., 2004). Moreover, the detection of residual primitive Philadelphia-positive cells in Imatinib-treated CML patients with complete cytogenetic remission (Graham et al., 2002; Bhatia et al., 2003) and the kinetics of disease relapse upon discontinuation of Imatinib in CML patients in clinical remission (Michor et al., 2005) are both consistent with the concept that the hematopoietic stem cell is the cell of origin for transformation by BCR/ABL. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Myeloid leukemias are heterogeneous malignancies in morphology, immunophenotype, genetic and epigenetic alterations, and response to therapy. This heterogeneity is thought to depend on the accumulation of secondary mutations enhancing proliferation/survival and/or blocking differentiation in a small subset of leukemia-initiating cells capable of self-renewal. This model of clonal evolution is based on xenotransplantation studies demonstrating that leukemia can be initiated and maintained in immunodeficient mice by a small subset of purified leukemic cells immunophenotypically similar to normal hematopoietic stem cells and is known as the leukemia stem cell model. Since its original formulation, many studies have validated the main conclusion of this model. However, recent data from xenotransplantation studies in more severely immunodeficient mice suggest that imunophenotype and behaviour of leukemic stem cells is more heterogeneous and "plastic" than originally thought. We will discuss here the evolution of the leukemia stem cell model and its impact for the therapy of patients with myeloid malignancies.
    Molecular Aspects of Medicine 06/2013; 39. DOI:10.1016/j.mam.2013.06.003 · 10.30 Impact Factor
Show more